Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection
Melhorn J. et al, (2023), Frontiers in Medicine, 10
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19
Kotanidis CP. et al, (2022), The Lancet Digital Health, 4, e705 - e716
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomic A. et al, (2022), Nature Communications, 13
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58
Persistence of inflammatory and vascular damage mediators 5 months after acute COVID-19
Petousi N. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60
Spontaneous pneumomediastinum, subcutaneous emphysema and pneumothorax in non-intubated patients with COVID-19 pneumonitis: a retrospective case note review of a single centre experience
Karwal R. et al, (2022), EUROPEAN RESPIRATORY JOURNAL, 60
Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant
Turnbull CD. et al, (2021), BMJ Open Respiratory Research, 8, e001044 - e001044
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
Skelly DT. et al, (2021), Nature Communications, 12
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abaleke E. et al, (2021), The Lancet, 397, 605 - 612
COMBINATION FIXED-DOSE BETA AGONIST AND STEROID INHALER AS REQUIRED FOR ADULTS OR CHILDREN WITH MILD ASTHMA: A COCHRANE SYSTEMATIC REVIEW
Fries A. et al, (2021), THORAX, 76, A24 - A24
EVALUATION OF MYCOBACTERIUM TUBERCULOSIS-SPECIFIC IFN-G, TNF-A, CXCL10, IL2, CCL2, CCL7 AND CCL4 LEVELS FOR ACTIVE TUBERCULOSIS DIAGNOSIS
Fries A. et al, (2021), THORAX, 76, A27 - A28
P170 Single centre experience on idiopathic pulmonary fibrosis patient tolerance of pirfenidone; impact on nurse-led ILD helpline usage
Rathnapala A. et al, (2016), Thorax, 71, A176.1 - A176
P175 Single centre experience of the real-life impact of pirfenidone on lung function in patients with idiopathic pulmonary fibrosis
Rathnapala A. et al, (2016), Thorax, 71, A179.1 - A179
S101 Single centre experience of switching patients with idiopathic pulmonary fibrosis from pirfenidone to nintedanib
Rathnapala A. et al, (2016), Thorax, 71, A60.1 - A60